CellMosaic ADC PerKits®

Download Documents
ADC FLYER
APPLICATION NOTE

Historically, antibody-drug conjugation was performed solely by drug developers, occasionally in collaboration with contract research organization (CRO). The cost of these services can be prohibitive for academia institutions and small biotech companies. During the screening stages, researchers often need to prepare various ADCs with different antibodies and drugs.

CellMosaic's ADC PerKits® are designed to prepare antibody-drug conjugation through surface amines or reduced thiols. Some kits are applicable for general payloads with specific functional groups, while others provide selected standard linker molecules conjugated to a chosen payload. Each kit includes the necessary reagents and protocols for attaching the selected payload to the customer’s antibody and purifying the final ADC. Customers only need to supply their antibody and standard lab equipment.

A typical CellMosaic personalized ADC kit yields approximately 2-3 mg of final ADC in buffer, with an average Drug-to-Antibody Ratio (DAR) of 2-4. Purity levels are typically >90%, with less than 5% unreacted payload remaining. Individual results may vary depending on the specific antibody system you are using and the hydrophobicity of your payload. The kit instructions are comprehensive and easy to follow, and the procedure can typically be completed within 4 to 6 hours, requiring less than 1 hour of hands-on time.

As of August 2024, customers from over 112 organizations worldwide have used CellMosaic's ADC kits.

Other products on the market for antibody screening may use a general secondary antibody or a general antibody affinity coupling (such as protein-A) to provide indirect conjugation. However, these indirect conjugation approaches can significantly affect the hydrodynamic size and physiological behaviors of ADCs (e.g., altering cleavage and degradation mechanisms). As a result, these products do not provide a fully representative approach for evaluating your novel ADC in screening or proof-of-concept (POC) studies.

Perkit® ADC Selection Guide

Product#	Protein	Drug	Scale of Reaction (Standard Kit)	Labeling Chemistry	Linkage
CM11429	IgG Ab	No drug (VC-PAB linker only)	1-3 mg	Reduced thiol	Releasable
CM51403	IgG Ab	Acid	1-3 mg	Surface amine	Stable
CM11410 (x1, x3)	IgG Ab	DM1	0.1 mg, 1-3 mg	Surface amine	Stable
CM11406 (x1, x3)	IgG Ab	Doxorubicin	1-3 mg	Surface amine	Stable
CM11407 (x1, x3)	IgG Ab	Methotrexate	1-3 mg	Surface amine	Stable
CM11409 (x1, x3)	IgG Ab	MMAE	0.1 mg, 1-3 mg	Reduced thiol	Releasable
CM11422 (x1, x3)	IgG Ab	MMAF	1-3 mg	Reduced thiol	Stable
CM11425 (x1, x3)	IgG Ab	MMAF	1-3 mg	Reduced thiol	Releasable
CM11408 (x1, x3)	IgG Ab	SN38	1-3 mg	Surface amine	Releasable
CM11431 (x1, x3)	IgG Ab	Deruxtecan	1-3 mg	Reduced thiol	Releasable
CM11416 (x1, x3)	F(ab')2	MMAE	0.73-2.2 mg	Reduced thiol	Releasable
CM11419 (x1, x3)	F(ab')2	DM1	0.73-2.2 mg	Surface amine	Stable

(Note: additional kit configurations can be added upon customer request. Please inquire if your desired configuration is not listed, or request a custom bioconjugation service.)

AqT® ADC Drug Development & Manufacturing

When a drug conjugate cannot be synthesized using classical linkers, or when the effectiveness of the drug conjugate is compromised by the number of toxins loaded onto the antibody, CellMosaic has developed novel, super-hydrophilic, high-loading AqueaTether® (AqT®) linkers to address these challenges. For more information about AqT® technologies, please click here. To learn how to access this technology for your novel ADC development. Click here for more information.

Selected Citations from Customers who Use ADC Prepared from CellMosaic's ADC Kits

1. Lofgren, Kristopher A.; Sreekumar, Sreeja; Jenkins, Charles E., Jr.; Ernzen, Kyle J.; Kenny, Paraic A. "Anti-tumor efficacy of an MMAE-conjugated antibody targeting cell surface TACE/ADAM17-cleaved Amphiregulin in breast cancer." Antibody Therapeutics 2021, 4 (4), 252-261.

2. Neetha Parameswaran, Liping Luo, Lingjun Zhang, Joel Chen, Frank P. DiFilippo, Charlie Androjna, David A. Fox, Sarah L. Ondrejka, Eric D. Hsi, Deepa Jagadeesh, Daniel J. Lindner & Feng Lin. "CD6-targeted antibody-drug conjugate as a new therapeutic agent for T cell lymphoma" Leukemia 2023, 37, 2050-2057.

3. Micalizzi, Douglas S.; Che, Dante: Nicholson, Benjamin T.; Edd, Jon F.; Desai, Niyati; Lang, Evan R.; Toner, Mehmet; Maheswaran, Shyamala; Ting, David T.; Haber, Daniel A. "Targeting breast and pancreatic cancer metastasis using a dual-cadherin antibody." PNAS 2022, 43 (119), e2209563119.

3. Guido J J Kierkels, Eline van Diest, Patricia Hernández-López, Wouter Scheper, Anja C M de Bruin, Elselien Frijlink, Tineke Aarts-Riemens, Sanne F J van Dooremalen, Dennis X Beringer, Rimke Oostvogels, Lovro Kramer, Trudy Straetemans, Wolfgang Uckert, Zsolt Sebestyén, Jürgen Kuball. "Characterization and modulation of anti-αβTCR antibodies and their respective binding sites at the βTCR chain to enrich engineered T cells" Mol Ther Methods Clin Dev. 2021, 22, 388-400.

4. Zehua Sun, Xiaojie Chu, Cynthia Adams, Tatiana V Ilina, Michel Guerrero, Guowu Lin, Chuan Chen, Dontcho Jelev, Rieko Ishima, Wei Li, John W Mellors, Guillermo Calero, Dimiter S Dimitrov. "Preclinical assessment of a novel human antibody VH domain targeting mesothelin as an antibody-drug conjugate" Mol Ther Oncolytics 2023 31:100726. doi: 10.1016/j.omto.2023.09.002. eCollection 2023 Dec 19.